Authors


Matthew J. Wieduwilt, MD, PhD

Latest:

Chemotherapy-Free Regimens Gain Ground in Older Patients With ALL

While there have been exciting advancements in the treatment of B-cell acute lymphoblastic leukemia over the course of the past decade, the treatment of older adults remains a challenge.


Anna Jo Bodurtha Smith, MD, MPH, MSc

Latest:

Obstacles to Accessing Gynecologic Oncology Care With Insurance in the US

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses her research on issues facing patients who need care for gynecologic cancers who have private insurance in the United States.


Janet L. Abrahm, MD, FACP, FAAHPM

Latest:

Grief’s Hidden Role in Oncologist Compassion Fatigue and Burnout

Janet L. Abrahm, MD, FACP, FAAHPM, discussed the high rates of oncologist burnout and compassion fatigue.


Deborah Toppmeyer, MD

Latest:

Empowering Women Through Early Breast Cancer Detection: Taking Control of Your Health

For Breast Cancer Awareness Month, Deborah Toppmeyer, MD, emphasizes the crucial role of early breast cancer detection.


Sham Mailankody, MBBS

Latest:

Future Treatment Landscape for Early Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS, looks to the future treatment landscape for early relapsed/refractory multiple myeloma and addresses ways to improve patient access to care.


Megan Hollasch

Latest:

Higher Tivozanib Dose Improves Antitumor Activity in Kidney Cancer

Tivozanib at 1.34 mg showed greater antitumor activity than 0.89 mg, with similar hypertension rates, in kidney cancer.


Sponsored by Amgen Oncology

Latest:

Accelerating Precision Medicine for Cancer Patients

Tremendous strides in science have led to a wave of precision medicine-based approaches for patients that consider each patient’s underlying genetics and what makes each patient’s cancer unique.


Laura W. Dillon, PhD, FACMG

Latest:

Improved MRD Detection Methods Aid in Posttransplant AML

Adaptation of improved methods of MRD detection are needed to better define this population at risk.


Kerry King Minor, MSN, ANP-BC

Latest:

Chronic GVHD: Prognoses and Future Directions in Care

Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.



Ariel Perez, MD

Latest:

Retrospective Study of Pola-BR for R/R LBCL

Ariel Perez, MD, discusses polatuzumab vedotin in combination with bendamustine and rituximab since garnering approval from the FDA and studies that evaluated the combination.


Gene G. Finley, MD

Latest:

Advice to Community Oncologists Treating SCLC

Gene G. Finley, MD, provides advice to community oncologists who are treating patients with small cell lung cancer.


Julia K. Rotow, MD

Latest:

HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches

Panelists discuss second-line treatment options and emerging approaches for HER2-mutated non–-small cell lung cancer (NSCLC), highlighting novel therapies and clinical strategies.


Matthew Fowler

Latest:

High Predictive Value Is Observed for Circulating Tumor Tissue in Oropharyngeal Cancer

Results from a study evaluating circulating tumor tissue–modified viral (TTMV)–human papillomavirus (HPV) DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma is of interest.


Matthew Hadfield, DO

Latest:

Managing Immunotherapy Toxicities: Key Insights for Smaller and Resource-Limited Settings

Matthew Hadfield, DO, discusses what community oncologists should know about immunotherapy toxicities.


Ashley Yocum, PhD

Latest:

Yocum Discusses Updated Data From the Beat AML Master Trial

Ashley Yocum, PhD, discusses the Beat AML trial of biomarker-based treatments in acute myeloid leukemia.


Kevin Kunzmann

Latest:

Impact of the 2021 Lung Cancer Screening Guideline Update on Black Patients 1 Year Later

Select racial groups have benefitted from important updates made to the USPSTF lung cancer screening guideline a year ago.


Warner Kornberg

Latest:

Building a Patient-Centered Ecosystem Leads to Better Care

Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.


Noah M. Merin, MD, PhD

Latest:

Mechanism of Action Influences Sequencing of Systemic GVHD Therapies

Noah M. Merin, MD, PhD, discusses the mechanisms of action and sequencing of oral therapies for chronic graft-vs-host disease (GVHD) in a live virtual event.


Robert Holloway, MD

Latest:

Racial Disparities and Unmet Needs in Endometrial Cancer

Robert Holloway, MD, highlights the issue of racial disparity in endometrial cancer, and the critical unmet needs for patients.


Matthew Kurian, MD

Latest:

Expanding 177Lutetium-PSMA-617 Use in the Community

Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.



Paul Lammers, MD, MSc

Latest:

Next Steps in Cell Therapy

Paul Lammers, MD, MSc, talks about the future of cell therapies and the applications of TAC-01 in solid tumors.


Alexandra Gomez Arteaga, MD

Latest:

Advancements in Stem Cell Transplantation: Comparing Orca-T With PTCy

Alexandra Gomez Arteaga, MD, discusses the rationale behind a retrospective study comparing Orca-T with posttransplant cyclophosphamide-based hematopoietic cell transplantation.


Elizabeth Davis, MD

Latest:

The Future of Research in PEComas

The panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.


Marcus Neubauer, MD

Latest:

Precision Medicine Implemented in the Community Oncology Setting

Technology plays a pivotal role in enhancing precision medicine within cancer care.


Jia Ruan, MD, PhD

Latest:

Azacitadine Demonstrates Efficacy in a Phase 2 Trial of PTCL

Jia Ruan, MD, PhD, discusses the results of the multicenter phase 2 trial of oral azacitidine plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in patients with peripheral T-cell lymphoma.


Jason M. Hafron, MD, CMO

Latest:

Expert Explores Trials in CIS-Refractory Bladder Cancer

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.


Anne Wooford, MD

Latest:

Haploidentical Transplant for Patients Without HLA-Matched Donors

Anne Wooford, MD, provides background on her presentation around allogeneic stem cell transplant for the 2022 Transplantation & Cellular Therapy Meetings.